Beeline Medicines

Beeline Medicines is a clinical-stage biotechnology company developing precision therapies for autoimmune and inflammatory diseases. The company officially debuted on April 15, 2026 with $300 million in Series A financing led by Bain Capital and an initial five-program pipeline in-licensed from Bristol Myers Squibb. Its lead asset, afimetoran, is a once-daily oral dual Toll-like receptor 7/8 inhibitor in Phase 2 development for systemic lupus erythematosus, with plans to move into pivotal development after the current study. The broader pipeline also includes BMS-986326, an IL-2-CD25 fusion protein in Phase 1b for atopic dermatitis and lupus, lomedeucitinib, an oral TYK2 inhibitor in Phase 2 for plaque psoriasis, and two IND-stage next-generation biologics directed at the IL-18 and IL-10 pathways. The company is focused on potentially best-in-class or first-in-disease immune therapeutics and is headquartered across Stamford, Connecticut and Boston, Massachusetts.